Search research articles
Contact Us
Filters
Showing results (1331-1340 of 1,421) with videos related to
Page
of 143
Sort By:
The Lancet. Oncology
|
April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Biorxiv : the Preprint Server for Biology
|
June 6, 2022
Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques
Cyril Le Nouën, Christine E Nelson, Xueqiao Liu, et al.
JAMIA Open
|
February 7, 2020
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
Michael J Pishvaian, Edik M Blais, R Joseph Bender, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S Banerjee, A M Oza, M J Birrer, et al.
Gynecologic Oncology
|
December 15, 2021
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study
Elizabeth M Swisher, Carol Aghajanian, David M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
October 14, 2022
Ectonucleoside triphosphate diphosphohydrolase-1 (CD39) impacts TGF-β1 responses: insights into cardiac fibrosis and function following myocardial infarction
Tatiana Novitskaya, Shamama Nishat, Roman Covarrubias, et al.
Frontiers in Oncology
|
January 3, 2022
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Hoyoung M Maeng, Brittni N Moore, Hadi Bagheri, et al.
The Lancet. Oncology
|
April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
J F Liu, K N Moore, M J Birrer, et al.
Page
of 143
Search research articles
Search
Showing results (1331-1340 of 1,421) with videos related to
Sort By:
Page
of 143
The Lancet. Oncology
|
April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Biorxiv : the Preprint Server for Biology
|
June 6, 2022
Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques
Cyril Le Nouën, Christine E Nelson, Xueqiao Liu, et al.
JAMIA Open
|
February 7, 2020
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
Michael J Pishvaian, Edik M Blais, R Joseph Bender, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S Banerjee, A M Oza, M J Birrer, et al.
Gynecologic Oncology
|
December 15, 2021
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study
Elizabeth M Swisher, Carol Aghajanian, David M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
October 14, 2022
Ectonucleoside triphosphate diphosphohydrolase-1 (CD39) impacts TGF-β1 responses: insights into cardiac fibrosis and function following myocardial infarction
Tatiana Novitskaya, Shamama Nishat, Roman Covarrubias, et al.
Frontiers in Oncology
|
January 3, 2022
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Hoyoung M Maeng, Brittni N Moore, Hadi Bagheri, et al.
The Lancet. Oncology
|
April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
J F Liu, K N Moore, M J Birrer, et al.
Page
of 143